According to FutureWise analysis the market for allogeneic t cell therapies in 2023 was US$ 1.21 billion, and is expected to reach US$ 1.46 billion by 2031 at a CAGR of 10%. Allogeneic T-cell therapies are a form of immunotherapy that leverage T cells derived from healthy donors to treat a variety of diseases, with a primary focus on cancer. This innovative therapeutic approach begins with...